153 related articles for article (PubMed ID: 28838714)
41. Intracranial Responses to Afatinib at Different Doses in Patients With EGFR-mutated Non-small-cell Lung Carcinoma and Brain Metastases.
Wei YF; Lim CK; Tsai MS; Huang MS; Chen KY
Clin Lung Cancer; 2019 May; 20(3):e274-e283. PubMed ID: 30930121
[TBL] [Abstract][Full Text] [Related]
42. Clinical significance of monitoring EGFR mutation in plasma using multiplexed digital PCR in EGFR mutated patients treated with afatinib (West Japan Oncology Group 8114LTR study).
Akamatsu H; Koh Y; Okamoto I; Fujimoto D; Bessho A; Azuma K; Morita S; Yamamoto N; Nakagawa K
Lung Cancer; 2019 May; 131():128-133. PubMed ID: 31027689
[TBL] [Abstract][Full Text] [Related]
43. Targeting angiogenesis for patients with unresectable malignant pleural mesothelioma.
Tsao A; Nakano T; Nowak AK; Popat S; Scagliotti GV; Heymach J
Semin Oncol; 2019 Apr; 46(2):145-154. PubMed ID: 31280996
[TBL] [Abstract][Full Text] [Related]
44. Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study.
Ho GF; Chai CS; Alip A; Wahid MIA; Abdullah MM; Foo YC; How SH; Zaatar A; Lam KS; Leong KW; Low JS; Yusof MM; Lee EC; Toh YY; Liam CK
BMC Cancer; 2019 Sep; 19(1):896. PubMed ID: 31500587
[TBL] [Abstract][Full Text] [Related]
45. Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in.
Nowak AK; Lesterhuis WJ; Kok PS; Brown C; Hughes BG; Karikios DJ; John T; Kao SC; Leslie C; Cook AM; Pavlakis N; Briscoe K; O'Byrne KJ; Karapetis CS; Lam WS; Langford A; Yip S; Stockler MR
Lancet Oncol; 2020 Sep; 21(9):1213-1223. PubMed ID: 32888453
[TBL] [Abstract][Full Text] [Related]
46. Distinct Afatinib Resistance Mechanisms Identified in Lung Adenocarcinoma Harboring an EGFR Mutation.
Yamaoka T; Ohmori T; Ohba M; Arata S; Murata Y; Kusumoto S; Ando K; Ishida H; Ohnishi T; Sasaki Y
Mol Cancer Res; 2017 Jul; 15(7):915-928. PubMed ID: 28289161
[TBL] [Abstract][Full Text] [Related]
47. Phase 2 Study of Afatinib Alone or Combined With Bevacizumab in Chemonaive Patients With Advanced Non-Small-Cell Lung Cancer Harboring EGFR Mutations: AfaBev-CS Study Protocol.
Ninomiya T; Ishikawa N; Inoue K; Kubo T; Yasugi M; Shibayama T; Maeda T; Fujitaka K; Kodani M; Yokoyama T; Kuyama S; Ochi N; Ueda Y; Miyoshi S; Kozuki T; Amano Y; Kubota T; Sugimoto K; Bessho A; Ishii T; Watanabe K; Oze I; Hotta K; Kiura K
Clin Lung Cancer; 2019 Mar; 20(2):134-138. PubMed ID: 30514667
[TBL] [Abstract][Full Text] [Related]
48. Afatinib in advanced pretreated non-small-cell lung cancer- a Canadian experience.
Ezeife DA; Melosky B; Tudor R; Lin S; Lau A; Panzarella T; Leighl NB
Curr Oncol; 2018 Oct; 25(5):e385-e390. PubMed ID: 30464688
[TBL] [Abstract][Full Text] [Related]
49. Comprehensive Pharmacogenomic Profiling of Malignant Pleural Mesothelioma Identifies a Subgroup Sensitive to FGFR Inhibition.
Quispel-Janssen JM; Badhai J; Schunselaar L; Price S; Brammeld J; Iorio F; Kolluri K; Garnett M; Berns A; Baas P; McDermott U; Neefjes J; Alifrangis C
Clin Cancer Res; 2018 Jan; 24(1):84-94. PubMed ID: 29061644
[No Abstract] [Full Text] [Related]
50. Duration of treatment among patients prescribed afatinib or erlotinib as first-line therapy for EGFR mutation-positive non-small-cell lung cancer in the USA.
Lim J; Samuelsen C; Golembesky A; Shrestha S; Wang L; Griebsch I
Future Oncol; 2019 May; 15(13):1493-1504. PubMed ID: 30888202
[No Abstract] [Full Text] [Related]
51. A phase II trial of EGFR-TKI readministration with afatinib in advanced non-small-cell lung cancer harboring a sensitive non-T790M EGFR mutation: Okayama Lung Cancer Study Group trial 1403.
Oda N; Hotta K; Ninomiya K; Minami D; Ichihara E; Murakami T; Yokoyama T; Ichikawa H; Chikamori K; Takigawa N; Ochi N; Harita S; Maeda Y; Kiura K
Cancer Chemother Pharmacol; 2018 Dec; 82(6):1031-1038. PubMed ID: 30276451
[TBL] [Abstract][Full Text] [Related]
52. Association of ERBB Mutations With Clinical Outcomes of Afatinib- or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma: Secondary Analysis of the LUX-Lung 8 Randomized Clinical Trial.
Goss GD; Felip E; Cobo M; Lu S; Syrigos K; Lee KH; Göker E; Georgoulias V; Li W; Guclu S; Isla D; Min YJ; Morabito A; Ardizzoni A; Gadgeel SM; Fülöp A; Bühnemann C; Gibson N; Krämer N; Solca F; Cseh A; Ehrnrooth E; Soria JC
JAMA Oncol; 2018 Sep; 4(9):1189-1197. PubMed ID: 29902295
[TBL] [Abstract][Full Text] [Related]
53. Prospective exosome-focused translational research for afatinib study of non-small cell lung cancer patients expressing EGFR (EXTRA study).
Okuma Y; Morikawa K; Tanaka H; Yokoyama T; Itani H; Horiuchi K; Nakagawa H; Takahashi N; Bessho A; Soejima K; Kishi K; Togashi A; Kanai Y; Ueda K; Horimoto K; Matsutani N; Seki N
Thorac Cancer; 2019 Feb; 10(2):395-400. PubMed ID: 30536780
[TBL] [Abstract][Full Text] [Related]
54. Co-occurring Mutations of Tumor Suppressor Genes,
Tranchant R; Quetel L; Tallet A; Meiller C; Renier A; de Koning L; de Reynies A; Le Pimpec-Barthes F; Zucman-Rossi J; Jaurand MC; Jean D
Clin Cancer Res; 2017 Jun; 23(12):3191-3202. PubMed ID: 28003305
[No Abstract] [Full Text] [Related]
55. Real-world study of afatinib in first-line or re-challenge settings for patients with EGFR mutant non-small cell lung cancer.
Tanaka H; Taima K; Itoga M; Ishioka Y; Baba K; Shiratori T; Sakamoto H; Tsuchiya J; Nakagawa H; Hasegawa Y; Yasugahira H; Okudera K; Takanashi S; Tasaka S
Med Oncol; 2019 May; 36(6):57. PubMed ID: 31089973
[TBL] [Abstract][Full Text] [Related]
56. Amplification of MET in a Patient with Malignant Pleural Mesothelioma.
Varesano S; Salvi S; Boccardo S; Ravetti JL; Ferro P; Canessa PA; Fedeli F; Pistillo MP; Roncella S
J Thorac Oncol; 2015 Oct; 10(10):e103-4. PubMed ID: 26398828
[No Abstract] [Full Text] [Related]
57. Proton-coupled folate transporter as a biomarker of outcome to treatment for pleural mesothelioma.
Petri GL; Cascioferro S; Parrino B; Peters GJ; Diana P; Giovannetti E
Pharmacogenomics; 2018 Jul; 19(10):811-814. PubMed ID: 29916298
[No Abstract] [Full Text] [Related]
58. Response to afatinib in treatment-naïve patients with advanced mutant epidermal growth factor receptor lung adenocarcinoma with brain metastases.
Li SH; Liu CY; Hsu PC; Fang YF; Wang CC; Kao KC; Tseng LC; Yang CT
Expert Rev Anticancer Ther; 2018 Jan; 18(1):81-89. PubMed ID: 29172778
[TBL] [Abstract][Full Text] [Related]
59. Differential significance of molecular subtypes which were classified into EGFR exon 19 deletion on the first line afatinib monotherapy.
Tokudome N; Koh Y; Akamatsu H; Fujimoto D; Okamoto I; Nakagawa K; Hida T; Imamura F; Morita S; Yamamoto N
BMC Cancer; 2020 Feb; 20(1):103. PubMed ID: 32028909
[TBL] [Abstract][Full Text] [Related]
60. Epigenetic Modifier UHRF1 May Be a Potential Target in Malignant Pleural Mesothelioma.
Baird AM; Finn SP; Gray SG; Sheils O
J Thorac Oncol; 2021 Jan; 16(1):14-16. PubMed ID: 33384056
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
